Cargando…
An ETP model (exclusion-tolerance-progression) for multi drug resistance
BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131929/ https://www.ncbi.nlm.nih.gov/pubmed/15857507 http://dx.doi.org/10.1186/1742-4682-2-17 |
_version_ | 1782123961983696896 |
---|---|
author | Kannan, Subburaj |
author_facet | Kannan, Subburaj |
author_sort | Kannan, Subburaj |
collection | PubMed |
description | BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive to resistant cell populations. RESULTS: Based on findings from clinical and experimental studies, a unifying model is proposed to delineate the potential mechanism by which tumor cells progress towards multi drug resistance, resulting in failure of chemotherapy. CONCLUSION: It is suggested that the evolution of multi drug resistance is a developmentally orchestrated event. Identifying stage-specific time windows during this process would help to identify valid therapeutic targets for the effective elimination of malignancy. |
format | Text |
id | pubmed-1131929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11319292005-05-20 An ETP model (exclusion-tolerance-progression) for multi drug resistance Kannan, Subburaj Theor Biol Med Model Research BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive to resistant cell populations. RESULTS: Based on findings from clinical and experimental studies, a unifying model is proposed to delineate the potential mechanism by which tumor cells progress towards multi drug resistance, resulting in failure of chemotherapy. CONCLUSION: It is suggested that the evolution of multi drug resistance is a developmentally orchestrated event. Identifying stage-specific time windows during this process would help to identify valid therapeutic targets for the effective elimination of malignancy. BioMed Central 2005-04-27 /pmc/articles/PMC1131929/ /pubmed/15857507 http://dx.doi.org/10.1186/1742-4682-2-17 Text en Copyright © 2005 Kannan; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kannan, Subburaj An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title | An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title_full | An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title_fullStr | An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title_full_unstemmed | An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title_short | An ETP model (exclusion-tolerance-progression) for multi drug resistance |
title_sort | etp model (exclusion-tolerance-progression) for multi drug resistance |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131929/ https://www.ncbi.nlm.nih.gov/pubmed/15857507 http://dx.doi.org/10.1186/1742-4682-2-17 |
work_keys_str_mv | AT kannansubburaj anetpmodelexclusiontoleranceprogressionformultidrugresistance AT kannansubburaj etpmodelexclusiontoleranceprogressionformultidrugresistance |